Source: Eur Respir J 2009; 33: 1383-1388
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Kreuter M., Kropff M., Fischaleck A., Junker K., Gerss J., Heinecke A., Lindermann M., Reinmuth N., Berdel W. E., Mesters R. M., Thomas M.. Prognostic relevance of angiogenesis in stage III NSCLC receiving multimodality treatment. Eur Respir J 2009; 33: 1383-1388

Member's Comments

No comment yet.

Related content which might interest you: Different morphological changes in non-small cell lung cancers and their corresponding lymph node metastases after neoadjuvant therapy? Source: Eur Respir J 2004; 24: Suppl. 48, 479s Year: 2004 A novel biologic classification of non-small cell lung cancer Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology Year: 2005 Staging and restaging in the era of multimodality treatment Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006 Neo-adjuvant chemotherapy: level of evidence in early stage and in marginally resectable disease Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts Year: 2005 Surgical multimodality treatment for stage III non-small cell lung cancer (NSCLC) Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006 Prognostic factors in resected pathological N1-stage II nonsmall cell lung cancer Source: Eur Respir J 2013; 41: 649-655 Year: 2013 Age and stage at presentation in lung cancer Source: Annual Congress 2005 - Management of lung cancer: clinical problems Year: 2005 Accuracy of re-mediastinoscopy and fusion PET-CT in the assessment of lymph node (LN) downstaging after induction chemotherapy for N2 non-small cell lung cancer (NSCLC) Source: Eur Respir J 2006; 28: Suppl. 50, 602s Year: 2006 Prevalence of silent brain metastasis (BM) in the initial staging of non-small cell lung carcinoma (NSCLC) Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients Year: 2011 Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer Source: Annual Congress 2011 - General thoracic surgery II Year: 2011 Prognostic factors in patients with resected pathologic stage I and II nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 269s Year: 2002 Prognostic factors in pathological stage IB nonsmall cell lung cancer greater than 3 cm Source: Eur Respir J 2010; 36: 1355-1361 Year: 2010 Objective measurement of tumor central location can predict nodal involvement in patients with cT1N0M0 non-small cell lung cancer Source: Virtual Congress 2020 – Screening and early lung cancer Year: 2020 Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007 Which definition of a central tumour is more predictive of occult mediastinal metastasis in nonsmall cell lung cancer patients with radiological N0 disease? Source: Eur Respir J, 53 (3) 1801508; 10.1183/13993003.01508-2018 Year: 2019 Role of chemotherapy in stage III non-small cell lung cancer (NSCLC): adjuvant or induction? Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006 Staging of lung cancer Source: Eur Respir Mon; 2009: 44: 150–168 Year: 2009 Analysis of risk factors for brain metastasis in locally advanced stage non-small cell carcinoma Source: Annual Congress 2010 - Best supportive care and palliation for lung cancer patients Year: 2010